Top Markets
#1 Palladium Network Palladium Network +27.94%
#2 MarsCoin MarsCoin +25.78%
#3 Hive Hive +25.60%
#4 Siren Siren +24.48%
#5 BankrCoin BankrCoin +20.74%
#6 Ankr Network Ankr Network +17.93%
#7 StonkBroker StonkBroker +16.54%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#9 Status Status +11.03%
#10 Provenance Blockchain Provenance Blockchain +8.81%
Coin of the day
Palladium Network Palladium Network
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
Classifica tra le azioni #18268
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Prezzo delle azioni
$1.79
Ultima sincronizzazione: 2026-09-02
Capitalizzazione di mercato
$205.75M
Variazione (1 giorno)
3.18%
Variazione (1 anno)
-61.61%
Paese
US
Scambia NovaBridge Biosciences (NBP)

Categoria

Healthcare
Rapporto P/S per NovaBridge Biosciences (NBP)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di NovaBridge Biosciences, il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per NovaBridge Biosciences da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH